Subject
Cardiology and Cardiovascular Medicine
Reference15 articles.
1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N. Engl. J. Med.,2016
2. Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places;Luconi;Nutr. Metab. Cardiovasc. Dis.,2016
3. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors;Grempler;Diabetes Obes. Metab.,2012
4. Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients;von Lewinski;Metabolism,2010
5. Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart;Vrhovac;Pflugers Arch.,2015
Cited by
132 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献